Wright John W, Mizutani Shigehiko, Harding Joseph W
Departments of Psychology and Veterinary and Comparative Anatomy, Pharmacology, and Physiology and Programs in Neuroscience and Biotechnology, Washington State University, P.O. Box 644820, Pullman, WA 99164-4820, USA.
Int J Hypertens. 2012;2012:124758. doi: 10.1155/2012/124758. Epub 2012 Jun 26.
The classic renin-angiotensin system (RAS) was initially described as a hormone system designed to mediate cardiovascular and body water regulation. The discovery of a brain RAS composed of the necessary functional components (angiotensinogen, peptidases, angiotensins, and specific receptor proteins) independent of the peripheral system significantly expanded the possible physiological and pharmacological functions of this system. This paper first describes the enzymatic pathways resulting in active angiotensin ligands and their interaction with AT(1), AT(2), and mas receptor subtypes. Recent evidence points to important contributions by brain angiotensin III (AngIII) and aminopeptidases A (APA) and N (APN) in sustaining hypertension. Next, we discuss current approaches to the treatment of hypertension followed by novel strategies that focus on limiting the binding of AngII and AngIII to the AT(1) receptor subtype by influencing the activity of APA and APN. We conclude with thoughts concerning future treatment approaches to controlling hypertension and hypotension.
经典肾素-血管紧张素系统(RAS)最初被描述为一种旨在介导心血管和机体水调节的激素系统。由独立于外周系统的必要功能成分(血管紧张素原、肽酶、血管紧张素和特定受体蛋白)组成的脑RAS的发现,显著扩展了该系统可能的生理和药理功能。本文首先描述了产生活性血管紧张素配体的酶促途径及其与AT(1)、AT(2)和mas受体亚型的相互作用。最近的证据表明,脑内血管紧张素III(AngIII)以及氨肽酶A(APA)和氨肽酶N(APN)在维持高血压方面起着重要作用。接下来,我们讨论当前治疗高血压的方法,随后是通过影响APA和APN的活性来限制AngII和AngIII与AT(1)受体亚型结合的新策略。我们最后思考了控制高血压和低血压的未来治疗方法。